Fennec Pharmaceuticals Inc. (FENC) is a commercial-stage specialty pharmaceutical company based in Research Triangle Park, North Carolina, that markets PEDMARK, the only FDA-approved therapy shown to reduce the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors. The stock rose 4.82%, or $0.56, to $12.18 on Monday afternoon, compared with Friday's closing price of $11.62. The direction was decisively higher, and the immediate driver was identifiable: a sell-side price target increase published before the opening bell that reaffirmed the post-earnings demand narrative.
The dominant catalyst was B. Riley Securities raising its 12-month price target on FENC to $19 from $18 while reiterating a Buy rating. The size of the target increase was modest, but the substance of the note mattered more than the headline number. Analyst Madison El-Saadi argued that underlying demand for PEDMARK grew roughly 20% to 25% sequentially in the third quarter, well ahead of the 13% sequential growth in reported net sales, with a mix shift toward academic centers obscuring the underlying trajectory.
The note also laid out a sequence of potential re-rating triggers in early 2027: formal fiscal 2027 guidance, a $100 million annualized revenue run rate, and earnings-per-share expansion against a largely fixed cost base. It further flagged interim City of Hope data in adult metastatic germ cell tumors due in early January, a dataset that could support broader guideline recommendations and a materially larger addressable market. That framing is what turned a one-dollar target bump into a buying impulse.
The advance also extends a rally that began after the November 12 quarterly report. Net product sales reached $19.4 million, up 56% year over year and the eighth consecutive quarter of growth. Adjusted EBITDA hit a record $5.8 million, or 30% of net product sales, operating cash flow reached $6.7 million, and cash rose to $48.7 million with no debt. Earnings of $0.12 per share beat the $0.09 consensus, and revenue of $19.61 million topped expectations of roughly $18.9 million.
Management highlighted the largest-ever carryover of patients, planned infusions, and vials into the fourth quarter, alongside a strong October and a new formulary win at a large Midwestern academic center. Those disclosures give the analyst upgrade something concrete to build on, which is why the stock has now gained in three of the last four sessions.
Volume was clearly elevated. Roughly 400,000 shares had changed hands by mid-afternoon, about four times the average of approximately 101,000 shares over the prior 60 sessions, and a larger turnover than Friday's already-heavy 285,000 shares. The buying was concentrated in the opening hour, when the stock gapped up and printed its high of $12.88 before fading through the afternoon.
The move was notably idiosyncratic. The S&P 500 fell about 2% and the Nasdaq-100 roughly 2.7%, while the closely watched biotech ETF tracking small and mid-cap drug developers dropped around 2.7%. Fennec rose anyway, a divergence that points to company-specific demand rather than sector sympathy. Technically, shares pushed through the $11.60–$12.13 area that capped Friday's advance and now sit above their short- and medium-term moving averages; the August high of $13.25 is the next reference point. The 52-week range runs from $5.65 to $13.25, and short interest of roughly 455,000 shares as of October 30 is too small to explain the move on its own.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 32 out of 100.
The verified news was moderate rather than transformative: a single analyst target increase from $18 to $19 on a company with a market capitalization near $430 million, albeit one accompanied by a substantive demand argument and a clear catalyst calendar. The price move was close to twice the stock's typical absolute daily change of about 2.6% over the last 60 sessions, but swings of similar or larger size occurred six times in that window, including four moves above 6%. Strong-but-not-exceptional news paired with a move that is large yet familiar for this name produces a mid-30s score.
The near-term calendar is dense. Management hosts one-on-one investor meetings at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, followed by a fireside chat at the Piper Sandler Healthcare Conference on December 3. Fourth-quarter and full-year 2026 results are expected in the first quarter of 2027, with management guiding to the lowest cash operating expense quarter of the year and full-year cash operating costs in the low $50 million range.
Two fundamental tests dominate. First, whether the record patient and infusion carryover converts into sequential revenue growth, given the four-to-six-month lag between enrollment and completed infusion. Second, the City of Hope interim data in early January, which could move PEDMARK closer to expanded guideline recommendations for adult and metastatic patients. Risks include decelerating year-over-year growth, dependence on a single product, pricing pressure from compounded sodium thiosulfate alternatives, an unsigned Japan licensing partnership, and the absence of formal guidance. Consensus among the five covering analysts remains a Strong Buy with an average target near $17.20.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the selection rotates as market conditions change. Reviewing the current leaderboard is a practical way to see which automated strategies are working right now and how they are positioned across individual names and broader themes.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where FENC declined for three days, in 225 of 274 cases, the price declined further within the following month. The odds of a continued downward trend are 82%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
FENC broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for FENC entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on FENC as a result. In 81 of 113 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for FENC just turned positive on November 09, 2026. Looking at past instances where FENC's MACD turned positive, the stock continued to rise in 35 of 47 cases over the following month. The odds of a continued upward trend are 74%.
FENC moved above its 50-day moving average on November 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where FENC advanced for three days, in 203 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.105) is normal, around the industry mean (3.498). FENC has a moderately low P/E Ratio (-81.750) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.100) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (5.963) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. FENC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FENC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of therapeutic products based on cell adhesion
Industry Biotechnology